Dr. Joel Randolph Hecht, MD

Dr. Hecht practices at UCLA Santa Monica Medical Center in Santa Monica, California, part of University of California Health.

Dr. Hecht's NPI, 1790703742, was assigned on July 18, 2006. Dr. Hecht graduated from Eastern Virginia Medical School in 1984. Dr. Hecht's California license number on file is G63119.

Dr. Hecht's primary practice is UCLA Santa Monica Medical Center, at 1250 16th Street, Santa Monica, CA 90404 in Los Angeles County. The practice phone is (310) 319-4000.

Dr. Hecht's primary practice is UCLA Santa Monica Medical Center in Santa Monica, California, part of University of California Health. Dr. Hecht is also affiliated with Ronald Reagan UCLA Medical Center. The medical group on file is UCLA Medical Group. Dmand AI also links Dr. Hecht to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Hecht practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Hecht's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Hecht is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Hecht's licenses on file in 2 states: California and Illinois.

Dmand AI lists acid reflux among the conditions Dr. Hecht treats.

CMS data shows 9,677 Medicare services from Dr. Hecht across 21 procedure codes in 2024, for 255 Medicare patients. Medicare paid $90,963 for them.

CMS counts 255 Medicare patients who saw Dr. Hecht in 2024. The largest group is 65 to 74, with 134 patients. 71% of them have high cholesterol, and 67% have high blood pressure. 18% are also on Medicaid. Their average risk score is 2.68, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Hecht's median patient age at 67, with 49% women.

In 2024, Dr. Hecht wrote 114 Medicare Part D claims for 34 patients. 76% of them were for generic drugs. CMS names the drug for 37 of them, across 2 drugs with 11 or more claims each, at $46,869 in total drug cost. In 2022, CMS named 12 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Hecht for performance year 2024, reported as part of a group. Dr. Hecht accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Hecht as offering telehealth.

Dmand AI links 12 papers to Dr. Hecht, published from 2005 to 2023. 2015 was the busiest year, with 2. The most frequent topics are Colorectal Neoplasms. Dr. Hecht has published most often in J Clin Oncol. Dr. Hecht's most frequent co-authors are Leonard Saltz, MD, Paulo M. Hoff, MD and Herbert Hurwitz, MD.

Dmand AI links Dr. Hecht to 8 clinical trials, 3 of them phase 1/2 studies. 2 are still active or recruiting. Conditions studied include Rectal Diseases, Colorectal Neoplasms and Rectal Neoplasms. Gilead Sciences sponsors the most, 2. Open Payments lists research payments to Dr. Hecht that name 1 trial.

CMS Open Payments shows 168 general payments to Dr. Hecht from 30 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 71% of the total. Genentech, Inc. paid the most, $26,228. It also lists 8 research payments totaling $18,487 from 2017 to 2025, naming 1 clinical trial.

Dmand AI lists 2 awards for Dr. Hecht.

Dr. Hecht graduated from Eastern Virginia Medical School in 1984. Dr. Hecht is a member of ASCO and Society for Immunotherapy of Cancer.

Dr. Hecht is in network with 6 carriers, including Blue Cross Blue Shield of Michigan, Blue Cross Blue Shield of Massachusetts and HCSC. Medicare plans come from the most carriers, 5. Check the plan with the practice before a visit.